Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07675109 · ClinicalTrials.gov registry record · NA
Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)
A NA study, sponsored by Noctrix Health.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT07675109: Recruiting NA study, sponsored by Noctrix Health.
NCT07675109 is a NA study that is actively recruiting participants, run by Noctrix Health. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07675109, a NA study, is actively recruiting participants, sponsored by Noctrix Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.
Primary Outcome
This outcome measures the number of awakenings per night that were related to RLS symptoms. A lower number represents a better outcome. Assessed via daily sleep diary and compared for each intervention to the Baseline period
Interventions
- DEVICE Investigational Extended Duration (XD-) TOMAC Therapy
- DEVICE Tonic Motor Activation (TOMAC) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT07675109 shows while recruiting
NCT07675109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Investigational Extended Duration (XD-) TOMAC Therapy is the first listed.
NCT07675109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07675109 about?
NCT07675109 is a clinical study titled "Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)". This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.
What is the current status of trial NCT07675109?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-06-08. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07675109?
The interventions under investigation include: Investigational Extended Duration (XD-) TOMAC Therapy (DEVICE), Tonic Motor Activation (TOMAC) Therapy (DEVICE).
Who is sponsoring clinical trial NCT07675109?
This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07675109's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI